|
|
Reference
|
|
  
|
Abramson, J.S., Feldman, T., Kroll-Desrosiers, A.R., Muffly, L.S., Winer, E., Flowers, C.R., Lansigan, F., Nabhan, C., Nastoupil, L.J., Nath, R., Goy, A., Castillo, J.J., Jagadeesh, D., Woda, B., Rosen, S.T., Smith, S.M., Evens, A.M. (2014) Peripheral T-cell lymphomas in a large US multicenter cohort: Prognostication in the modern era including impact of frontline therapy. Annals of Oncology, 25(11): 2211-2217
|
|
|
Advani, R.H., Ansell, S.M., Lechowicz, M.J., Beaven, A.W., Loberiza, F., Carson, K.R., Evens, A.M., Foss, F., Horwitz, S., Pro, B., Pinter-Brown, L.C., Smith, S.M., Shustov, A.R., Savage, K.J. (2016) A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T-cell consortium trial. British Journal of Haematology, 172(4): 535-544
|
|
|
Amengual, J.E., Lichtenstein, R., Rojas, C., et al. (2016) The pralatrexate-romidepsin doublet: A well tolerated and highly effective combination for patients with relapsed or refractory peripheral T-cell lymphoma. Blood, 128: 1824A
|
|
|
Asano, N., Suzuki, R., Kagami, Y., Ishida, F., Kitamura, K., Fukutani, H., Morishima, Y., Takeuchi, K., Nakamura, S. (2005) Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. American Journal of Surgical Pathology, 29(10): 1284-1293
|
|
|
Attygalle, A.D., Kyriakou, C., Dupuis, J., Grogg, K.L., Diss, T.C., Wotherspoon, A.C., Chuang, S.S., Cabeçadas, J., Isaacson, P.G., du Ming-Qing,, Gaulard, P., Dogan, A. (2007) Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: Clinical correlation and insights into natural history and disease progression. American Journal of Surgical Pathology, 31(7): 1077-1088
|
|
|
Avila, M., Aquilar, H., Demichelis, G.R., et al. (2018) Effectiveness of L-asparaginase-based regimens compared to anthracycline-based regimens in newly diagnosed extranodal NK/T-cell lymphoma, nasal type: A single Mexican center experience. Blood Res, 53(3): 210-227
|
|
|
Barr, P.M., Li, H., Spier, C., Mahadevan, D., Leblanc, M., Ul, H.M., Huber, B.D., Flowers, C.R., Wagner-Johnston, N.D., Horwitz, S.M., Fisher, R.I., Cheson, B.D., Smith, S.M., Kahl, B.S. (2015) Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. Journal of Clinical Oncology, 33(21): 2399-2404
|
|
|
Bayle, C., Charpentier, A., Duchayne, E., Manel, A., Pages, M., Robert, A., Lamant, L., Dastugue, N., Bertrand, Y., Dijoud, F., Emile, J., Machover, D., Brugieres, L., Delsol, G. (1999) Leukaemic presentation of small cell variant anaplastic large cell lymphoma: Report of four cases. British Journal of Haematology, 104(4): 680-688
|
|
|
Biggar, R.J., Engels, E.A., Frisch, M., Goedert, J.J. (2000) Risk of T-cell lymphomas in persons with AIDS. Journal of Acquired Immune Deficiency Syndromes, 26(4): 371-376
|
|
|
Bu, S., Yuan, F., Wei, X., Yin, Q., Li, Y., Mi, R., Yang, H., Li, H., Ge, S., Liu, Y., Song, Y. (2016) L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma. Experimental and Therapeutic Medicine, 11(6): 2437-2445
|
|
|
Carson, K.R., Horwitz, S.M., Pinter-Brown, L.C., Rosen, S.T., Pro, B., Hsi, E.D., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L.A., Acosta, M.A., Shustov, A.R., Advani, R.H., Feldman, T.A. (2017) A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer, 123(7): 1174-1183
|
|
|
Castellar, E.R.P., Jaffe, E.S., Said, J.W., et al. (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood, 124(9): 1473-80
|
|
|
Chan, J.K., Tsang, W.Y., Ng, C.S. (1996) Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: The neoplastic cells are often CD3 epsilon. Blood, 87(2): 839-841
|
|
|
Clemens, M.W., Brody, G.S., Mahabir, R.C., Miranda, R.N. (2018) How to diagnose and treat breast implant-associated anaplastic large cell lymphoma. Plastic and Reconstructive Surgery, 141(4): 586e-599e
|
|
|
Corradini, P., Dodero, A., Zallio, F., Caracciolo, D., Casini, M., Bregni, M., Narni, F., Patriarca, F., Boccadoro, M., Benedetti, F., Rambaldi, A., Gianni, A.M., Tarella, C. (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. Journal of Clinical Oncology, 22(11): 2172-2176
|
|
|
Cuadros, M., Dave, S.S., Jaffe, E.S., Honrado, E., Milne, R., Alves, J., Rodríguez, J., Zajac, M., Benitez, J., Staudt, L.M., Martinez-Delgado, B. (2007) Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. Journal of Clinical Oncology, 25(22): 3321-3329
|
|
|
Damaj, G., Gressin, R., Bouabdallah, K., Cartron, G., Choufi, B., Gyan, E., Banos, A., Jaccard, A., Park, S., Tournilhac, O., Schiano, de C.J., Voillat, L., Joly, B., Le, G.S., Saad, A. (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY trial. Journal of Clinical Oncology, 31(1): 104-110
|
|
|
d'Amore F., Gaulard, P., Trümper, L., Corradini, P., Kim, W.-S., Specht, L., Bjerregaard, P.M., Ladetto, M. (2015) Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26(suppl 26): v108-v115
|
|
|
d'Amore Francesco,, Relander, T., Lauritzsen, G.F., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Österborg, A., Merup, M., Brown, P., Kuittinen, O., Erlanson, M., Østenstad, B., Fagerli, U., Gadeberg, O.V. (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. Journal of Clinical Oncology, 30(25): 3093-3099
|
|
|
de Jong, D., Vasmel, W.L., de Boer, J.P., et al. (2008) Anaplastic large-cell lymphoma in women with breast implants. JAMA, 300(17): 2030-2035
|
|
|
de Leval, L., Gaulard, P. (2008) Pathobiology and molecular profiling of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program, 2008(1): 272-279
|
|
|
de Leval, L., Rickman, D.S., Thielen, C., de Reynies, A., Huang, Y., Delsol, G., Lamant, L., Leroy, K., Brière, J., Molina, T., Berger, F., Gisselbrecht, C., Xerri, L., Gaulard, P. (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood, 109(11): 4952-4963
|
|
|
Delarue, R., Dupuis, J., Sujobert, P., Barbieux, S., Marçais, A., Tournilhac, O., Lachenal, F., Cheminant, M., Sarkozy, C., Fataccioli, V., Morschhauser, F., Hermine, O., Haioun, C., Gaulard, P. (2016) Treatment with hypomethylating agent 5-azacytidine induces sustained response in angioimmunoblastic T cell lymphomas. Blood, 128(22): 4164A
|
|
|
Dupuis, J., Emile, J.-F., Mounier, N., Gisselbrecht, C., Martin-Garcia, N., Petrella, T., Bouabdallah, R., Berger, F., Delmer, A., Coiffier, B., Reyes, F., Gaulard, P. (2006) Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood, 108(13): 4163-4169
|
|
|
Dupuis, J., Boye, K., Martin, N., et al. (2006) Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): A new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol, 30(4): 490-494
|
|
|
Ellin, F., Landström, J., Jerkeman, M., Relander, T. (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry. Blood, 124(10): 1570-1577
|
|
|
Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., Macdonald, A.P., Repp, R., Schetelig, J., Seipelt, G., Österborg, A. (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103(8): 2920-2924
|
|
|
Fanale, M.A., Hagemeister, F.B., Fayad, L., Oki, Y., Fowler, N., Romaguera, J., Shah, N., Chuang, H., Feng, L., Horowitz, S.B., Wesson, E., Hutto, T.Y., Muzzafar, T., Samaniego, F., Davis, R. E. (2014) A phase I trial of alisertib plus romidepsin for relapsed/refractory aggressive B and T-cell lymphomas. Blood, 124(21): 1744A
|
|
|
Felgar, R.E., Macon, W.R., Kinney, M.C., et al. (1997) TIA-1 expression in lymphoid neoplasms: Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol, 150 (6): 1893-900
|
|
|
Ferreri, A.J.M., Govi, S., Pileri, S.A. (2012) Hepatosplenic gamma-delta T-cell lymphoma. Critical Reviews in Oncology/Hematology, 83(2): 283-292
|
|
|
Feyler, S., Prince, H.M., Pearce, R., Towlson, K., Nivison-Smith, I., Schey, S., Gibson, J., Patton, N., Bradstock, K., Marks, D.I., Cook, G. (2007) The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: A BSBMT and ABMTRR study. Bone Marrow Transplantation, 40(5): 443-450
|
|
|
Friedberg, J.W., Mahadevan, D., Cebula, E., Persky, D., Lossos, I., Agarwal, A.B., Jung, J., Burack, R., Zhou, X., Leonard, E. J., Fingert, H., Danaee, H., Bernstein, S.H. (2014) Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive band T-cell non-Hodgkin lymphomas. Journal of Clinical Oncology, 32(1): 44-50
|
|
|
Gambacorti, P.C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., Messa, C., Guerra, L., Giudici, G., Sala, E., Mussolin, L., Deeren, D., King, M.H., Steurer, M., Ordemann, R. (2014) Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. JNCI: Journal of the National Cancer Institute, 106(2): djt378
|
|
|
Gaulard, P., de Leval, L. (2014) Pathology of peripheral T-cell lymphomas: Where do we stand?. Seminars in Hematology, 51(1): 5-16
|
|
|
Gentille, C., Qin, Q., Barbieri, A., Sai, R.P., Iyer, S. (2017) Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. Ecancermedicalscience, 11: 771-771
|
|
|
Grogg, K.L., Morice, W.G., Macon, W.R. (2007) Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. British Journal of Haematology, 137(5): 416-422
|
|
|
Hari, P., Raj, R.V., Olteanu, H. (2016) Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma. New England Journal of Medicine, 375(15): 1501-1502
|
|
|
Holkova, B., Yazbeck, V., Kmieciak, M., Bose, P., Ma, S., Kimball, A., Tombes, M.B., Shrader, E., Wan, W., Weir-Wiggins, C., Singh, A., Hogan, K.T., Conine, S., Sankala, H., Roberts, J.D., Shea, T.C., Grant, S. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leukemia & Lymphoma, 58(6): 1349-1357
|
|
|
Horwitz, S., O'Connor, O.A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N.L., Christensen, J.H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W.S., Feldman, T., Lennard, A. (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial. Lancet, 393(10168): 229-240
|
|
|
Horwitz, S.M., Ansell, S.M., Ai, W.Z., Barnes, J., Barta, S.K., Choi, M., Clemens, M.W., Dogan, A., Greer, J.P., Halwani, A., Haverkos, B.M., Hoppe, R.T., Jacobsen, E., Jagadeesh, D., Kim, Y.H. (2018) NCCN guidelines insights: T-cell lymphomas: Version 2.2018. Journal of the National Comprehensive Cancer Network, 16(2): 123-135
|
|
|
Horwitz, S.M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J.D., Morrow, S.N., Allen, K., Douglas, M., Stern, H., Sweeney, J., Kelly, P., Kelly, V. (2018) Activity of the PI3K-d,g inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood, 131(8): 888-898
|
|
|
Iqbal, J., Wright, G., Wang, C., Rosenwald, A., Gascoyne, R.D., Weisenburger, D.D., Greiner, T.C., Smith, L., Guo, S., Wilcox, R.A., Teh, B.T., Lim, S.T., Tan, S.Y., Rimsza, L.M., Jaffe, E.S. (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood, 123(19): 2915-2923
|
|
|
Iqbal, J., Weisenburger, D.D., Greiner, T.C., Vose, J.M., Mckeithan, T., Kucuk, C., Geng, H., Deffenbacher, K., Smith, L., Dybkaer, K., Nakamura, S., Seto, M., Delabie, J., Berger, F., Loong, F., Au, W.Y. (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood, 115(5): 1026-1036
|
|
|
Islam, S., Vick, E., Huber, B., Morales, C., Spier, C., Cooke, L., Weterings, E., Mahadevan, D. (2017) Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: A novel therapeutic strategy. Oncotarget, 8(59): 100326-100338
|
|
|
Jaccard, A., Gachard, N., Marin, B., Rogez, S., Audrain, M., Suarez, F., Tilly, H., Morschhauser, F., Thieblemont, C., Ysebaert, L., Devidas, A., Petit, B., de Leval, L., Gaulard, P., Feuillard, J. (2011) Efficacy of L-asparaginase with methotrexate and Dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma: A phase 2 study. Blood, 117(6): 1834-1839
|
|
|
Jantunen, E., Boumendil, A., Finel, H., Luan, J., Johnson, P., Rambaldi, A., Haynes, A., Duchosal, M.A., Bethge, W., Biron, P., Carlson, K., Craddock, C., Rudin, C., Finke, J., Salles, G. (2013) Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: A retrospective study by the EBMT. Blood, 121(13): 2529-2532
|
|
|
Kanakry, J.A., Kasamon, Y.L., Gocke, C.D., Tsai, H., Davis-Sproul, J., Ghosh, N., Symons, H., Bolaños-Meade, J., Gladstone, D.E., Swinnen, L.J., Luznik, L., Fuchs, E.J., Jones, R.J. (2013) Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biology of Blood and Marrow Transplantation, 19(4): 602-606
|
|
|
Kim, B., Roth, C., Young, V. L., Chung, K.C., van Busum, K., Schnyer, C., Mattke, S. (2011) Anaplastic large cell lymphoma and breast implants. Plastic and Reconstructive Surgery, 128(3): 629-639
|
|
|
Kim, H.K., Moon, S.M., Moon, J.H., Park, J.E., Byeon, S., Kim, W.S. (2015) Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. Blood Research, 50(4): 254-256
|
|
|
Kim, S.J., Yoon, D.H., Kang, H.J., Kim, J.S., Park, S.K., Kim, H.J., Lee, J., Ryoo, B., Ko, Y.H., Huh, J., Yang, W.I., Kim, H.K., Min, S.K., Lee, S., Do, I., Suh, C., Kim, W.S. (2012) Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial. European Journal of Cancer, 48(17): 3223-3231
|
|
|
Kim, W.S., Song, S.-Y., Ahn, Y.C., Ko, Y.-H., Baek, C.-H., Kim, D.Y., Yoon, S.-S., Lee, H.G., Kang, W.K., Lee, H.J., Park, C.R., Park, K. (2001) CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma?. Annals of Oncology, 12(3): 349-352
|
|
|
Kinney, M.C., Collins, R.D., Greer, J.P., Whitlock, J.A., Sioutos, N., Kadin, M.E. (1993) A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. American Journal of Surgical Pathology, 17(9): 859-868
|
|
|
Kwong, Y., Kim, W.S., Lim, S.T., Kim, S.J., Tang, T., Tse, E., Leung, A.Y.H., Chim, C. (2012) SMILE for natural killer/T-cell lymphoma: Analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood, 120(15): 2973-2980
|
|
|
Kwong, Y., Chan, T.S.Y., Tan, D., Kim, S.J., Poon, L., Mow, B., Khong, P., Loong, F., Au-Yeung, R., Iqbal, J., Phipps, C., Tse, E. (2017) PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood, 129(17): 2437-2442
|
|
|
Kyriakou, C., Canals, C., Finke, J., Kobbe, G., Harousseau, J., Kolb, H., Novitzky, N., Goldstone, A.H., Sureda, A., Schmitz, N. (2009) Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 27(24): 3951-3958
|
|
|
Lanier, L.L., Testi, R., Bindl, J., Phillips, J.H. (1989) Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. Journal of Experimental Medicine, 169(6): 2233-2238
|
|
|
Lesokhin, A.M., Ansell, S.M., Armand, P., Scott, E.C., Halwani, A., Gutierrez, M., Millenson, M.M., Cohen, A.D., Schuster, S.J., Lebovic, D., Dhodapkar, M., Avigan, D., Chapuy, B., Ligon, A.H. (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study. Journal of Clinical Oncology, 34(23): 2698-2704
|
|
|
Li, L., Duan, W., Zhang, L., Li, X., Fu, X., Wang, X., Wu, J., Sun, Z., Zhang, X., Chang, Y., Nan, F., Yan, J., Li, Z., Young, K.H., Zhang, M. (2017) The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. British Journal of Haematology, 178(5): 772-780
|
|
|
Loch-Wilkinson, A., Beath, K.J., Knight, R.J.W., Wessels, W.L.F., Magnusson, M., Papadopoulos, T., Connell, T., Lofts, J., Locke, M., Hopper, I., Cooter, R., Vickery, K., Joshi, P.A. (2017) Breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand. Plastic and Reconstructive Surgery, 140(4): 645-654
|
|
|
Maeda, Y., Nishimori, H., Yoshida, I., Hiramatsu, Y., Uno, M., Masaki, Y., Sunami, K., Masunari, T., Nawa, Y., Yamane, H., Gomyo, H., Takahashi, T., Yano, T., Matsuo, K., Ohshima, K. (2017) Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: A multicenter phase II trial of West-JHOG PTCL0707. Haematologica, 102(12): 2097-2103
|
|
|
Mahadevan, D., Unger, J.M., Spier, C.M., Persky, D.O., Young, F., Leblanc, M., Fisher, R.I., Miller, T.P. (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group study S0350. Cancer, 119(2): 371-379
|
|
|
Makita, S., Maeshima, A.M., Maruyama, D., Izutsu, K., Tobinai, K. (2018) Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: An evidence-based review. OncoTargets and Therapy, Volume 11: 2287-2293
|
|
|
Malamut, G., Chandesris, O., Verkarre, V., Meresse, B., Callens, C., Macintyre, E., Bouhnik, Y., Gornet, J., Allez, M., Jian, R., Berger, A., Châtellier, G., Brousse, N., Hermine, O. (2013) Enteropathy associated T cell lymphoma in celiac disease: A large retrospective study. Digestive and Liver Disease, 45(5): 377-384
|
|
|
Mehta-Shah, N., Lunning, M.A., Boruchov, A.M., et al. (2015) A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma. J Clin Oncol, 33 (suppl 15): 8521A
|
|
|
Mehta-Shah, N., Moskowitz, A.J., Lunning, M., Lynch, P., Scheuerman, M., Kumar, A., Gerecitano, J.F., Zelenetz, A.D., Hamlin, P.A., Noy, A., Matasar, M.J., Palomba, M. L., Younes, A., Schaffer, W., Grewal, R. (2016) A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas. Blood, 128(22): 2991A
|
|
|
Moskowitz, A.J., Koch, R., Mehta-Shah, N., et al. (2017) In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-inhibitor in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma. Blood, 130 (suppl 1): 819A
|
|
|
Nijeboer, P., de Baaij, L.R., Visser, O., Witte, B.I., Cillessen, S.A.G.M., Mulder, C.J., Bouma, G. (2015) Treatment response in enteropathy associated T-cell lymphoma: Survival in a large multicenter cohort. American Journal of Hematology, 90(6): 493-498
|
|
|
O'Connor, O.A., Falchi, L., Lue, J.K., et al. (2019) Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: A multicenter phase I study. Blood, e pub ahead of print
|
|
|
O'Connor, O.A., Horwitz, S., Masszi, T., van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., Bhat, G., Choi, M.R., Walewski, J., Savage, K., Foss, F., Allen, L.F. (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study. Journal of Clinical Oncology, 33(23): 2492-2499
|
|
|
O'Connor, O.A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Jo, L.M., Savage, K.J., Shustov, A.R., Gisselbrecht, C., Jacobsen, E., Zinzani, P.L., Furman, R., Goy, A. (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. Journal of Clinical Oncology, 29(9): 1182-1189
|
|
|
Ogura, M., Ishida, T., Hatake, K., Taniwaki, M., Ando, K., Tobinai, K., Fujimoto, K., Yamamoto, K., Miyamoto, T., Uike, N., Tanimoto, M., Tsukasaki, K., Ishizawa, K., Suzumiya, J. (2014) Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Journal of Clinical Oncology, 32(11): 1157-1163
|
|
|
Oki, Y., Haverkos, B., Zain, J.M., Lechowicz, M.J., Devata, S., Korman, N.J., Ramchandren, R., Pinter-Brown, L.C., Barde, P.J., Nair, A., Huen, A. (2018) Tenalisib, a dual PI3K d/g inhibitor: Safety and efficacy results from an on-going phase I/Ib study in relapsed/refractory T-cell lymphoma. Journal of Clinical Oncology, 36(15_suppl): 7510-7510, ASCOAbstract
|
|
|
Park, S., Ko, Y.H. (2014) Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders. Journal of Dermatology, 41(1): 29-39
|
|
|
Perry, A.M., Warnke, R.A., Hu, Q., Gaulard, P., Copie-Bergman, C., Alkan, S., Wang, H., Cheng, J.X., Bacon, C.M., Delabie, J., Ranheim, E., Kucuk, C., Hu, X., Weisenburger, D.D., Jaffe, E.S. (2013) Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood, 122(22): 3599-3606
|
|
|
Petković, I. (2015) Current trends in the treatment of primary mediastinal large B-cell lymphoma: An overview. Współczesna Onkologia / Contemp Oncol, Poznan, 19(6): 428-435
|
|
|
Petrella, T., Maubec, E., Cornillet-Lefebvre, P., et al. (2007) Indolent CD8-positive lymphoid proliferation of the ear: A distinct primary cutaneous T-cell lymphoma. Am J Surg Pathol, 31(12): 1887-92
|
|
|
Poon, L., Kwong, Y. (2016) Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine. Annals of Hematology, 95(5): 847-849
|
|
|
Pro, B., Advani, R., Brice, P., Bartlett, N.L., Rosenblatt, J.D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J.M., Yang, Y., Sievers, E.L., Kennedy, D.A., Shustov, A. (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. Journal of Clinical Oncology, 30(18): 2190-2196
|
|
|
Qi, W., Spier, C., Liu, X., Agarwal, A., Cooke, L.S., Persky, D.O., Chen, D., Miller, T.P., Mahadevan, D. (2013) Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leukemia Research, 37(4): 434-439
|
|
|
Quintanilla-Martinez, L. (2017) The 2016 updated WHO classification of lymphoid neoplasias. Hematological Oncology, 35(S1): 37-45
|
|
|
Rodríguez-Pinilla, S.M., Atienza, L., Murillo, C., Pérez-Rodríguez, A., Montes-Moreno, S., Roncador, G., Pérez-Seoane, C., Domínguez, P., Camacho, F.I., Piris, M.A. (2008) Peripheral T-cell lymphoma with follicular T-cell markers. American Journal of Surgical Pathology, 32(12): 1787-1799
|
|
|
Sakata-Yanagimoto, M., Enami, T., Yoshida, K., et al. (2014) Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet, 46 (2): 171-5
|
|
|
Savage, K.J., Harris, N.L., Vose, J.M., Ullrich, F., Jaffe, E.S., Connors, J.M., Rimsza, L., Pileri, S.A., Chhanabhai, M., Gascoyne, R.D., Armitage, J.O., Weisenburger, D.D. (2008) ALK-negative anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood, 111(12): 5496-5504
|
|
|
Schmitz, N., Trümper, L., Ziepert, M., Nickelsen, M., Ho, A.D., Metzner, B., Peter, N., Loeffler, M., Rosenwald, A., Pfreundschuh, M. (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group S0350. Blood, 116(18): 3418-3425
|
|
|
Schmitz, N., de Leval, L. (2017) How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: Current practice and a glimpse into the future. British Journal of Haematology, 176(6): 851-866
|
|
|
Shustov, A., Coiffier, B., Horwitz, S., Sokol, L., Pro, B., Wolfson, J., Balser, B., Eisch, R., Popplewell, L., Prince, H. M., Allen, S.L., Piekarz, R., Bates, S. (2017) Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: Analysis of two phase II trials. Leukemia & Lymphoma, 58(10): 2335-2341
|
|
|
Sun, J.C., Lanier, L.L. (2011) NK cell development, homeostasis and function: Parallels with CD8+ T cells. Nature Reviews Immunology, 11(10): 645-657
|
|
|
Swerdlow, S.H., Jaffe, E.S., Brousset, P., et al., International Lymphoma Study Group (2014) Cytotoxic T-cell and NK-cell lymphomas: Current questions and controversies. Am J Surg Pathol, 38(10): e60-e71
|
|
|
Swerdlow, S.H., Campo, E., Harris, N.L., et al. (2008) WHO classification of tumours of haemotopoietic and lymphoid tissues. Geneva: World Health Organization
|
|
|
Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G.A., Zelenetz, A.D., Jaffe, E.S. (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20): 2375-2390
|
|
|
Tan, S.-Y., Ooi, A.-S., Ang, M.-K., Koh, M., Wong, J.-C., Dykema, K., Ngeow, J., Loong, S., Gatter, K., Tan, L.Y., Lim, L.-C., Furge, K., Tao, M., Lim, S.-T., Loong, F., Cheah, P.L., Teh, B.-T. (2011) Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia, 25(3): 555-557
|
|
|
Thanarajasingam, G., Edell, E.S., Markovic, S.M. (2016) Complete response of anaplastic lymphoma kinase-mutated refractory extranodal natural killer/T-cell lymphoma to crizotinib. Mayo Clinic Proceedings, 91(9): 1319-1320
|
|
|
Vose, J., Armitage, J., Weisenburger, D. (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. Journal of Clinical Oncology, 26(25): 4124-4130
|
|
|
Voss, M.H., Lunning, M.A., Maragulia, J.C., Papadopoulos, E.B., Goldberg, J., Zelenetz, A.D., Horwitz, S.M. (2013) Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: A single institution experience. Clinical Lymphoma Myeloma and Leukemia, 13(1): 8-14
|
|
|
Went, P., Agostinelli, C., Gallamini, A., Piccaluga, P.P., Ascani, S., Sabattini, E., Bacci, F., Falini, B., Motta, T., Paulli, M., Artusi, T., Piccioli, M., Zinzani, P.L., Pileri, S.A. (2006) Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score. Journal of Clinical Oncology, 24(16): 2472-2479
|
|
|
Witzig, T., Sokol, L., Jacobsen, E., Advani, R., Mondejar, R., Piris, M., Burrows, F., Melvin, C., Mishra, V., Scholz, C., Gualberto, A. (2017) Preliminary results from an open-label, phase II study of tipifarnib in relapsed or refractory peripheral T-cell lymphoma. Hematological Oncology, 35(S2): 251-252
|
|
|
Yamaguchi, M., Oguchi, M., Suzuki, R. (2018) Extranodal NK/T-cell lymphoma: Updates in biology and management strategies. Best Practice & Research Clinical Haematology, 31(3): 315-321
|
|
|
Yamaguchi, M., Tobinai, K., Oguchi, M., Ishizuka, N., Kobayashi, Y., Isobe, Y., Ishizawa, K., Maseki, N., Itoh, K., Usui, N., Wasada, I., Kinoshita, T., Hotta, T., Tsukasaki, K., Oshimi, K. (2012) Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: An updated analysis of the Japan Clinical Oncology Group study JCOG0211. Journal of Clinical Oncology, 30(32): 4044-4046
|
|
|
Yang, L., Liu, H., Xu, X., Wang, X., Huang, H., Shi, W., Jiang, S. (2013) Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Medical Oncology, 30(4): 720-720
|
|
|
Zinzani, P.L., Magagnoli, M., Bendandi, M., Orcioni, G. F., Gherlinzoni, F., Albertini, P., Pileri, S.A., Tura, S. (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Annals of Oncology, 9(12): 1351-1353
|
|
|
Zinzani, P.L., Venturini, F., Stefoni, V., Fina, M., Pellegrini, C., Derenzini, E., Gandolfi, L., Broccoli, A., Argnani, L., Quirini, F., Pileri, S., Baccarani, M. (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: Evaluation of the long-term outcome. Annals of Oncology, 21(4): 860-863
|
|
|
|
|